 |
 Video: What is a Stock Split?
|
|
|
| Silverback Therapeutics is a biopharmaceutical company focused on utilizing its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Co. has engineered SBT8230 to treat chronic hepatitis B virus by eliciting an anti-viral immune response through targeting TLR8 activation to the liver. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to the same TLR8 linker-payload as SBT6050, but with an average drug antibody ratio (DAR) of about two as opposed to the average DAR of about four used in SBT6050. According to our SBTX stock split history records, SBTX has had 0 splits. | |
|
SBTX (SBTX) has 0 splits in our SBTX stock split history database.
Looking at the SBTX stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SBTX shares, starting with a $10,000 purchase of SBTX, presented on a split-history-adjusted basis factoring in the complete SBTX stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/07/2020 |
|
| End date: |
11/08/2022 |
|
| Start price/share: |
$29.40 |
|
| End price/share: |
$5.87 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-80.03% |
|
| Average Annual Total Return: |
-56.78% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,996.71 |
|
| Years: |
1.92 |
|
|
|
|
|
